Thank you to our sponsor
**A Quick Look at ASENT 2023**

**Annual Meeting Overview**
ASENT 2023 is the premier neurotherapeutics conference where senior leaders from payers, providers, employers, investors, fast-growing startups, pharma, policymakers, funders and innovation centers in the neurology and neuroscience space gather to ask one question: how can we improve the process of bringing neurotherapeutics to market?

The conference content will focus on the latest science in neurotherapeutics including innovations across disease states, novel delivery systems, gene therapy and biomarkers, and of course the latest drug therapies and devices. The event features plenary sessions, panel discussions, networking meetings, outstanding pipeline presentations and poster sessions.

**MEETING DETAILS**

ASENT 2023 Meeting Dates
Monday, March 13 - Wednesday, March 15, 2023

VIRTUAL FORMATT ONLINE

**ABSTRACT SUBMISSIONS**


Abstract Submission Deadline
January 23, 2023

**REGISTRATION IS OPEN**

https://asent.org/Annual-Meeting

Annual Meeting Registration Deadline
March 13, 2023

**WHO ATTENDS**

Clinician-Investigators
Neuroscience Trainees
Neuroscientist Researchers
Industry Research Scientists
Clinicians
Advocacy Group Leaders
Chief Medical Officers
CEOs
Founders
Funders
Investors
Prescribers
Payers
Innovation Centers
Journal Editors
Health Journalists
Drug and Device Companies
Communication Companies
Health Systems
Chairs of Neurology
Executive Directors
FDA
NINDS
NIMH
NIA
All ARE WELCOME!

**WHAT IS ASENT?**

The American Society for Experimental Neurotherapeutics (ASENT) is an independent non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the process by which new therapies are made available to patients with neurological disorders. Its primary goal is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system.
Register for ASENT 2023

Online Registration

In light of these unique times, the American Society for Experimental Neurotherapeutics has decided to continue with our virtual format. However, in order to continue to offer an outstanding virtual conference, ASENT must charge a small fee to attend the meeting. Below you will find details on registration fees.

<table>
<thead>
<tr>
<th>Meeting Rates</th>
<th>Member Rate</th>
<th>Non Member Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAN Members</td>
<td>$140</td>
<td>$310</td>
</tr>
<tr>
<td>Academic</td>
<td>$175</td>
<td>$375</td>
</tr>
<tr>
<td>Advocacy</td>
<td>$75</td>
<td>$200</td>
</tr>
<tr>
<td>Clinician</td>
<td>$175</td>
<td>$375</td>
</tr>
<tr>
<td>Govt</td>
<td>$175</td>
<td>$225</td>
</tr>
<tr>
<td>Industry</td>
<td>$325</td>
<td>$575</td>
</tr>
<tr>
<td>Retired</td>
<td>$75</td>
<td>$200</td>
</tr>
<tr>
<td>Trainee</td>
<td>$0</td>
<td>$50</td>
</tr>
<tr>
<td>LMIC</td>
<td>$0</td>
<td>$0</td>
</tr>
</tbody>
</table>

TO REGISTER, VISIT: https://asent.org/Annual-Meeting
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Type</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MONDAY, MARCH 13, 2023</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00am - 11:30 am</td>
<td>Plenary</td>
<td><strong>Drug Discovery: The Last Mile in Bringing Drugs to Market</strong></td>
</tr>
<tr>
<td>11:30am - 11:45am</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>11:45am - 1:00pm</td>
<td>Concurrent Symposia</td>
<td><strong>The Brain-Gut Connection in Neurodegenerative Diseases</strong></td>
</tr>
<tr>
<td>1:00pm - 1:45pm</td>
<td>BREAK and Poster Review</td>
<td></td>
</tr>
<tr>
<td>1:45pm - 3:00pm</td>
<td></td>
<td><strong>Advances in the Molecular Pathogenesis and Therapeutics of ALS</strong></td>
</tr>
<tr>
<td>3:00pm - 4:00pm</td>
<td></td>
<td><strong>Poster Presentations</strong></td>
</tr>
<tr>
<td>4:00pm - 5:00pm</td>
<td></td>
<td><strong>Networking Breakout Rooms: Live Discussion with Speakers</strong></td>
</tr>
<tr>
<td><strong>TUESDAY, MARCH 14, 2023</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00am - 11:15am</td>
<td>Plenary</td>
<td><strong>Neuro-Enabled: Next Generation Prosthetics to Restore Function</strong></td>
</tr>
<tr>
<td>11:15am - 11:30am</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>11:30am - 12:45pm</td>
<td>Concurrent Symposia</td>
<td><strong>Adding Insult to Injury: The Role of Neuroinflammation in Acute Injury to the Nervous System</strong></td>
</tr>
<tr>
<td>12:45pm - 1:00pm</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>1:00pm - 3:00pm</td>
<td></td>
<td><strong>Pipeline Presentations</strong></td>
</tr>
<tr>
<td>3:00pm - 4:00pm</td>
<td></td>
<td><strong>Poster Presentations</strong></td>
</tr>
<tr>
<td>4:00pm - 5:00pm</td>
<td></td>
<td><strong>Networking Breakout Rooms: Live Discussion with Speakers</strong></td>
</tr>
</tbody>
</table>
## ASENT 2023 | SCHEDULE AT A GLANCE

### WEDNESDAY

<table>
<thead>
<tr>
<th>Time</th>
<th>Type</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00am - 11:15am</td>
<td>Plenary</td>
<td>Opportunities and Obstacles for Innovators Entering the Field of Neurotherapeutics</td>
</tr>
<tr>
<td>11:15am - 11:30am</td>
<td></td>
<td>BREAK</td>
</tr>
<tr>
<td>11:30am - 12:45pm</td>
<td>Concurrent Symposia</td>
<td>Emerging Targets and Novel Approaches in Parkinson’s Disease</td>
</tr>
<tr>
<td>12:45pm - 1:00pm</td>
<td></td>
<td>BREAK</td>
</tr>
<tr>
<td>1:00pm - 2:00pm</td>
<td></td>
<td>Networking Breakout Rooms: Live Discussion with Speakers</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 10:00 a.m. – 10:05 a.m. | Conference Welcome  
Jessica Smith  
Executive Director |
| 10:05 a.m. – 10:10 a.m. | Presidential Opening  
Thomas P. Sutula, MD, PhD, University of Wisconsin, Madison  
President |
| 10:10 a.m. – 11:30 a.m. | Presidential Symposium: Drug Discovery: The Last Mile in Bringing Drugs to Market  
Presented in partnership with the American Academy of Neurology’s Experimental Neurotherapeutics Section.  
Chair: Samuel A. Frank, MD, FAAN, FANA, Beth Israel Deaconess Medical Center  
Co-Chair: Lauren Reoma, MD, National Institute of Neurological Disorders and Stroke  
The majority of trial work embarked on by the neurologist and the bulk of industry funded trials are in the phase 2 and phase 3 design space. Often, the development process and resources are focused on earlier stage innovations and design, leading up to the pilot, first-in-human and early phase trials. Beyond initial innovations, building the “last mile” to the pivotal registration trial is key to bringing drugs to market. Important trial methodology structures, innovation in digital designs, and necessary understanding of regulatory safety concerns ensure that early innovation in the drug and device space result in market approvals for our patients. |
| 11:30 a.m. – 11:45 a.m. | PANEL DISCUSSION (LIVE) |

**FACULTY**

**Successes and Challenges Getting Gene Therapy to Registration**  
Allyson Berent, DVM, Foundation for Angelman Syndrome Therapeutics; Angelman Syndrome Biomarker and Outcome Measure Consortium

**Accelerated approval pathways and the condition of conditional approval: secrets to success**  
Samuel A. Frank, MD, FAAN, FANA, Beth Israel Deaconess Medical Center

**Health Maximization with Neurologic Therapeutics Through Fair Pricing and Fair Access**  
David Rind, MD, MSc, Institute for Clinical and Economic Review (ICER)
**Concurrent Symposium 1**

**The Brain-Gut Connection in Neurodegenerative Diseases**
Chair: Suhayl Dhib-Jalbut, MD, Rutgers University Medical School
Co-Chair: Sharon Tamir, Mitsubishi Tanabe

The gut microbiome is believed to play an important role in neurodevelopment, autoimmune, neurodegenerative, and behavioral disorders. Gut dysbiosis, characterized by alterations in intestinal microbial composition and function, is commonly observed in Multiple Sclerosis, Parkinson’s disease, Alzheimer’s disease and ALS. Experimental evidence indicate that gut dysbiosis dysregulates homeostasis of the immune system and its interaction of the latter with the central nervous system. It is believed that diet is one of the most important factors affecting gut microbiota. This symposium will address the influence of the gut microbiome on neurodevelopment, pathogenesis of neurodegenerative disorders, and potential for therapeutic intervention.

**FACULTY**

**The Gut Microbiome Regulates Microglia Reactivity in a Mouse Model of Parkinson’s Disease**
Sarkis Mazmanian, PhD, CalTech

**The Gut Microbiome in MS: What We Know and What We Don’t**
Sergio E Baranzini, Ph.D., University of California San Francisco

**Targeting the Microbiome With Dietary Fiber**
Liping Zhao, PhD, Rutgers University Medical School

**Concurrent Symposium 2**

**Novel Approaches to Therapy in Epilepsy**
Chair: Aditya Joshi, MD, University of Pennsylvania
Co-Chair: Amir Tamiz, PhD, NINDS

The treatment of epilepsy remains a vexing problem in spite of an ever-expanding armamentarium of anti-seizure drugs. This symposium will examine some of the work that is being done to accelerate the development of novel treatments for epilepsy.

**FACULTY**

**Transcranial Focused Ultrasound for Epilepsy: An Emerging New Technology**
Ellen Bubrick, MD, FAES, Brigham Health, Brigham and Women’s Hospital

**Finding therapies for refractory epilepsy: new directions for solving a difficult problem**
Karen Wilcox, PhD, NINDS Epilepsy Therapy Screening Program

**Crossing the blood brain barrier..and back**
Lisa Shafer, PhD, Cerebral Therapeutics

**Panel Discussion (Live)**
### DAY 1: MONDAY, March 13, 2023 (Cont.)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 p.m. – 1:45 p.m.</td>
<td>BREAK and Poster Review</td>
</tr>
</tbody>
</table>
| 1:45 p.m. – 3:00 p.m.   | **Symposium:** Advances in the Molecular Pathogenesis and Therapeutics of ALS  
                          Chair: Maral Mouradian, MD, Rutgers University Medical School  
                          Latest advances in elucidating the molecular pathogenesis of ALS and novel therapeutic strategies.  
                          **FACULTY**  
                          **Approaches to Precision Therapy in ALS**  
                          Robert H. Brown MD, DPhil, University of Massachusetts  
                          **Nuclear Pore Dysfunction in ALS and Neurodegeneration**  
                          Jeffrey D. Rothstein, MD, PhD, Johns Hopkins University  
                          **ALS Outcomes and Clinical Trial Design**  
                          Merit Cudkowicz, MD, MSC, Mass General Hospital  
                          **PANEL DISCUSSION (LIVE)** |
| 3:00 p.m. - 4:00 p.m.   | **Poster Panel Discussion 1**                                          
                          Chair: Carolyn Tallon, PhD, Johns Hopkins Drug Discovery  
                          Posters selected to be featured in the Poster Panel Discussion are chosen via the abstract submission process. ASENT welcomes encore abstracts that are relevant to the field of Neurotherapeutics. During this live poster discussion poster presenters will have 10 minutes to present their poster to a live audience and 2 minutes of Q&A for each poster presenter. This will limit our panel to 5 presentations.  
                          **See list of poster presentations on Page 14.** |
| 4:00 p.m. - 5:00 p.m.   | **Live Networking Rooms**                                              
                          Discover our interactive breakout rooms where you can connect live with our leading faculty from our Day 1 sessions. You will have the opportunity to ask questions and get more in depth on the topics that matter to you.  
                          **Day 1 Breakout Rooms**  
                          • Drug Discovery  
                          • Neurodegenerative Disease  
                          • Epilepsy  
                          • ALS  
                          Select your preferred breakout room during registration. But remember you can always move between rooms. |
## Symposium: Neuro-Enabled: Next Generation Prosthetics To Restore Function
Presented in partnership with the Japanese Society of Neurological Therapeutics

This society was established in 1983 with the aim of contributing toward the therapeutic progress in the field of neurology and for a decade ASENT and JSNT have welcomed speakers at each society’s respective annual meetings.

Chair: Kazuo Fujihara, MD, Fukushima Medical University School of Medicine  
Co-Chair: Aditya Joshi, MD, University of Pennsylvania

Neurological disorders that impair patients' abilities to interact with the world can have a devastating impact on their quality of life. Devices that act as interfaces between the brain and an "effector" can go a long way toward helping patients return to a more normal life. In this session, we present four exciting technologies which have the potential to "neuro-enable" patients to restore some of their lost function.

### FACULTY

**Cybernics Medical Innovation for Neurological Diseases-- Wearable Cyborg HAL, Cybernics Treatment, C-Cloud**  
Prof. Yoshiyuki Sankai, Center of Cybernics Research, University of Tsukuba

**Microcoil-based Magnetic Stimulation of the CNS**  
Shelley Fried, PhD, Harvard Medical School, MGH

**Brain Computer Interface for the Treatment of Chronic Stroke**  
Eric C. Leuthardt, MD, Washington University, St. Louis

**Artificial Neural Connections Through the Neural Interface**  
Professor Yukio Nishimura, Tokyo Metropolitan Institute of Medical Science

### PANEL DISCUSSION (LIVE)

**BREAK**
## Concurrent Symposium 3

**Adding Insult to Injury: The Role of Neuroinflammation in Acute Injury to the Nervous System**

Chair: Aditya Joshi, MD, University of Pennsylvania  
Co-Chair: Sharon Tamir, Mitsubishi Tanabe

There is emerging evidence that neuroinflammation may both mar and mend the nervous system after an acute injury (traumatic brain injury, traumatic spine injury, and acute stroke). In this symposium, we explore some of the newest data on how inflammation may be harnessed to repair the brain and spinal cord, while minimizing additional damage.

**FACULTY**

**Chronic neuroinflammation and the injured brain: therapeutic insights from microglial depletion models**  
David J. Loane, Ph.D., Trinity College, University of Dublin

**Is Neuroinflammation a Key Driver of Secondary Neurodegeneration Following Stroke?**  
Renee Turner, PhD, University of Adelaide, Australia

**Microglia Are Key Players Regulating Intraspinal and Systemic Neuro-Immune Cross-Talk After Spinal Cord Injury**  
Phillip Popovich, PhD, Ohio State University

**PANEL DISCUSSION (LIVE)**

## Concurrent Symposium 4

**Moving novel neurotechnologies across the valley of death**

Chair: Ludy Shih, MD, MMSc, Boston University Medical School  
Co-Chair: Steve Schachter, MD, Beth Israel Deaconess Medical Center/Harvard

Next generation neurotherapeutic devices are being developed to record, stimulate or block neural signaling and affect specific molecular or neurophysiologic mechanisms across a broad variety of neurologic conditions, including pain, epilepsy, movement disorders, stroke/brain injury, as well as neurodegenerative disorders. This session will cover perspectives and initiatives focused on preclinical and clinical development, as well as regulatory science development tools for new device developers hoping to bring new therapies to market.

**FACULTY**

**Bioelectronic Medicines: At an Inflection Point in an Exponential Growth Curve?**  
Kip Ludwig, PhD, University of Wisconsin

**What if electricity were a medicine? From concept to commercialization**  
Kate Rosenbluth, PhD, Cala Health

**Introduction to OSEL and Neurological Regulatory Science Tool Development activities**  
Ksenia Blinova, PhD, FDA

**PANEL DISCUSSION (LIVE)**
## DAY 2: TUESDAY, March 14, 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 p.m. – 3:00 p.m.</td>
<td><strong>PIPELINE PRESENTATIONS: Emerging Neurotherapeutics Pipeline</strong>&lt;br&gt;Chair: C. Anthony Altar, PhD, Splice Therapeutic&lt;br&gt;The ASENT Annual Meeting attracts leaders in neurotherapeutics from all over the world, in all neurologic disease states. Pipeline presentations increase exposure to strategic partners in life sciences who have supported novel approaches through partnerships or strategic investments.&lt;br&gt;&lt;br&gt;<strong>Full details on presenters can be found on page 15.</strong></td>
</tr>
<tr>
<td>3:00 p.m. - 4:00 p.m.</td>
<td><strong>Poster Panel Discussion 2</strong>&lt;br&gt;Chair: Carolyn Tallon, PhD, Johns Hopkins Drug Discovery&lt;br&gt;Posters selected to be featured in the Poster Panel Discussion are chosen via the abstract submission process. ASENT welcomes encore abstracts that are relevant to the field of Neurotherapeutics. During this live poster discussion poster presenters will have 10 minutes to present their poster to a live audience and 2 minutes of Q&amp;A for each poster presenter. This will limit our panel to 5 presentations.&lt;br&gt;&lt;br&gt;<strong>See list of poster presentations on Page 14.</strong></td>
</tr>
<tr>
<td>4:00 p.m. - 5:00 p.m.</td>
<td><strong>Live Networking Rooms</strong>&lt;br&gt;Discover our interactive breakout rooms where you can connect live with our leading faculty from our Day 2 sessions. You will have the opportunity to ask questions and get more in depth on the topics that matter to you. <strong>Day 2 Breakout Rooms</strong>&lt;br&gt;• Neuroinflammation in Acute Injury&lt;br&gt;• Devices in Neurotherapeutics&lt;br&gt;• Pipeline&lt;br&gt;Select your preferred breakout room during registration. But remember, you can always move between rooms.</td>
</tr>
</tbody>
</table>
### Symposium: Opportunities and Obstacles for Innovators Entering the Field of Neurotherapeutics

Chair: Dietrich Haubenberger, MD, MHSc, Neurocrine Biosciences  
Co-Chair: Ludy Shih, MD, MMSc, Boston University School of Medicine

There are growing opportunities for early career clinician-investigators to contemplate planning a career in the development and testing of novel neurotherapeutics, whether in the academic, government or industry setting. The goal of this session is to introduce trainees and early career faculty to skills needs assessment and training opportunities that may address the specific training needs required for this type of career.

**FACULTY**

**Considering a Career in Pharma**  
Martin Bednar, MD, Takeda

**Potential Paths in Academics**  
Laurie Gutmann, MD, Indiana University School of Medicine

**Clinical Research Training Programs and Career Pathways at NINDS and Beyond**  
Lauren Reoma, MD, Clinical Trials Unit, NINDS

**PANEL DISCUSSION (LIVE)**
### Concurrent Symposium 5
**Emerging targets and novel approaches in Parkinson’s Disease**

Chair: Debra Ehrlich, MD, NINDS  
Co-Chair: Amir Tamiz, PhD, NINDS  

This session will bring perspectives from industry and academia to discuss novel approaches for therapeutics development in Parkinson’s disease.

**FACULTY**

**Developing Novel Therapeutics for Parkinson’s Disease: Opportunities, Challenges and Learnings from other Neurodegenerative Diseases**

Warren D. Hirst, PhD, Biogen  

**Biomarkers for Inflammation in Parkinson’s Disease**

David Standaert, MD, PhD, University of Alabama at Birmingham  

**Targeting chronic inflammation driven by soluble TNF to reduce risk and progression of neurodegenerative diseases**

Malú Tansey, PhD, University of Florida  

**PANEL DISCUSSION (LIVE)**

### Concurrent Symposium 6
**Discovery and Development of Psychedelics for Neuropsychiatric Disorders**

Chairs: Gail Farfel, PhD, ProMIS  
Co-Chair: Carolyn Tallon, PhD, Johns Hopkins University  

Neuropsychiatric disorders have been notoriously difficult to develop effective and well tolerated therapeutics. This session will cover the recent advancements in the use of psilocybin to treat neuropsychiatric disorders and explore the exciting new doors being opened for developing psychedelics for therapeutic use.

**FACULTY**

**Psilocybin Therapy: Evidence for a Novel, Rapid, and Enduring Antidepressant Agent**

Joshua Woolley, MD, PhD, UCSF  

**Early Development Strategy and Patenting of Psychedelics**

Nathan Bryson, PhD, Reunion Med  

**Development Strategies for the Evaluation of Psychedelic Compounds as Psychiatric Disorder Treatments**

Rob Silva, Ph.D., MindMed  

**PANEL DISCUSSION (LIVE)**

---

**Break**

**Live Networking Rooms**

Discover our interactive breakout rooms where you can connect live with our leading faculty from our Day 3 sessions. You will have the opportunity to ask questions and get more in depth on the topics that matter to you.

**Day 3 Breakout Rooms**

- Parkinson’s Disease  
- Psychedelics  
- Careers in Neurotherapeutics  
- Pipeline
### Poster Panel Discussion 1: Featured Posters

**Monday March 13, 2023 at 3pm ET**

<table>
<thead>
<tr>
<th>Poster 13</th>
<th>Dectin-1 signaling on colonic γδ T cells promotes psychosocial stress responses - Xiaolei Zhu, M.D., Ph.D., Johns Hopkins University</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 14</td>
<td>EEG Phenotyping as a loop translation tool to Identify and select new neurotherapeutics - Venceslas Duveau, Ph.D., SynapCell SAS</td>
</tr>
<tr>
<td>Poster 15</td>
<td>The amygdala-kindling model: Toward the development of a high performance screening platform to accelerate the identification of novel anti-seizure medications - Julien Volle, Ph.D., SynapCell SAS</td>
</tr>
<tr>
<td>Poster 16</td>
<td>Opening the blood-brain barrier for drug and gene therapy with MRI-guided TMS: A feasibility study - Ira Weinberg, M.D., Ph.D., Weinberg Medical Physics, Inc.</td>
</tr>
</tbody>
</table>

### Poster Panel Discussion 2: Featured Posters

**Tuesday March 14, 2023 at 3pm ET**

<table>
<thead>
<tr>
<th>Poster 12</th>
<th>Metaplastic effects of ketamine metabolite (2R,6R)-hydroxynorketamine on hippocampal synaptic plasticity and transmission in mice – Kyle A. Brown, Ph.D., University of Maryland School of Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster 17</td>
<td>Ampicillin for Major Depressive Disorder by Targeting Glial Glutamate Transporter in an Animal Model - Shafiqur Rahman PhD, South Dakota State University</td>
</tr>
<tr>
<td>Poster 18</td>
<td>Bidirectional transcription at the PPP2R2B gene locus in spinocerebellar ataxia type 12 - Pan P. Li, Ph.D., Johns Hopkins University School of Medicine</td>
</tr>
<tr>
<td>Poster 19</td>
<td>The expression of PPP2R2B gene in spinocerebellar ataxia type 12 is affected by the length and composition of the CAG repeat - Pan P. Li, Ph.D., Johns Hopkins University School of Medicine</td>
</tr>
<tr>
<td>Poster 20</td>
<td>Disease modifying effects of gut microbiome balancing-biological response modifier glucans in Parkinson’s disease – Results of a pilot clinical study - Samuel JK Abraham M.D., Ph.D., FRCP(L), University of Yamanashi</td>
</tr>
</tbody>
</table>
### Pipeline Presentations

**Tuesday March 14, 2023 at 1pm ET**

| Presentation 1 - Poster 10 | CLINICAL STAGE | XEN1101, a novel potassium channel modulator: interim data from an ongoing, long-term, open-label extension of a phase 2b study (X-TOLE) in adults with focal epilepsy - Jacqueline French, M.D., New York University Grossman School of Medicine and NYU Langone Health |
| Presentation 2 - Poster 1 | DISCOVERY | D-DPTIP is a dendrimer-conjugated nSMase2 inhibitor with targeted brain delivery and robust efficacy in a preclinical model of AD - Rana Rais, Ph.D., Johns Hopkins Drug Discovery |
| Presentation 3 - Poster 2 | DISCOVERY | Gut infiltration of Lcn-2+ Neutrophil is associated with gut dysbiosis and intestinal inflammation in a spontaneous EAE model of multiple sclerosis – Sudhir Kumar Yadav, PhD, Rutgers Robert Wood Johnson Medical School |
| Presentation 4 - Poster 3 | DISCOVERY | Dual inhibitors targeting neuroinflammation (NLRP3 inflammasome) and cholinergic pathway as novel therapeutic agents for Alzheimer’s Disease - Vikas Singh, MD, MHSA, FAES, University of Kansas Medical Center |
| Presentation 5 - Poster 4 | PRECLINICAL | GM6 Impact on TDP-43 levels in human TDP-43 tg mice may be therapeutic for ALS, and frontotemporal lobar degeneration (FTLD) - Mark S. Kindy, Ph.D., University of South Florida |
| Presentation 6 - Poster 5 | PRECLINICAL | ATH-1105, a small molecule positive modulator of hepatocyte growth factor (HGF)/MET, is neuroprotective in a TDP-43 mouse model of amyotrophic lateral sclerosis - Andree-Anne Berthiaume, Ph.D., Athira Pharma |
| Presentation 7 - Poster 6 | PRECLINICAL | Discovery and characterization of BHV-7000: a novel KV7.2/7.3 activator for the treatment of epilepsy - Steven Dworetzky, Ph.D., Biohaven Pharmaceuticals |
| Presentation 8 - Poster 7 | CLINICAL STAGE | NPT520-34, a clinical stage small molecule therapeutic candidate that targets neurodegenerative processes arising from mitochondrial dysfunction in Parkinson’s disease and other neurodegenerative disorders - Diana L. Price, Ph.D., Neuporpe Therapies, Inc. |
| Presentation 9 - Poster 8 | CLINICAL STAGE | MONARCH and ADMIRAL Interim Analyses: Ongoing, Open-label, Phase 1/2a Studies in US and UK Investigating Safety and Drug Exposure of STK-001, an Antisense Oligonucleotide (ASO), in Children and Adolescents with Dravet Syndrome (DS) - Javier Avendano, M.D., Stoke Therapeutics |
| Presentation 10 - Poster 9 | CLINICAL STAGE | Valbenazine effects on the dopamine system in humans, as measured by [11C]-PHNO positron emission tomography (PET) - Daniel Albrecht, Ph.D., Neurocrine Biosciences, Inc. |
## POSTERS/PIPELINES

<table>
<thead>
<tr>
<th>#</th>
<th>TITLE</th>
<th>AUTHORS/CONTACTS</th>
<th>STAGE</th>
<th>TYPE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td><strong>D-DPTIP is a dendrimer-conjugated nSMase2 inhibitor with targeted brain delivery and robust efficacy in a preclinical model of AD</strong></td>
<td>Rana Rais, Ph.D., Johns Hopkins Drug Discovery</td>
<td>DISCOVERY</td>
<td>Poster, Pipeline</td>
</tr>
<tr>
<td>2</td>
<td><strong>Gut infiltration of Lcn-2+ Neutrophil is associated with gut dysbiosis and intestinal inflammation in a spontaneous EAE model of multiple sclerosis</strong></td>
<td>Sudhir Kumar Yadav, Ph.D., Rutgers Robert Wood Johnson Medical School</td>
<td>DISCOVERY</td>
<td>Poster, Pipeline</td>
</tr>
<tr>
<td>3</td>
<td><strong>Dual inhibitors targeting neuroinflammation (NLRP3 inflammasome) and cholinergic pathway as novel therapeutic agents for Alzheimer’s Disease</strong></td>
<td>Vikas Singh, M.D., MHSA, FAES, University of Kansas Medical Center</td>
<td>DISCOVERY</td>
<td>Poster, Pipeline</td>
</tr>
<tr>
<td>4</td>
<td><strong>GM6 Impact on TDP-43 levels in human TDP-43 tg mice may be therapeutic for ALS, and frontotemporal lobar degeneration (FTLD)</strong></td>
<td>Mark S. Kindy, Ph.D., University of South Florida Dorothy Ko, MS, Genevorn</td>
<td>PRECLINICAL</td>
<td>Poster, Pipeline</td>
</tr>
<tr>
<td>5</td>
<td><strong>ATH-1105, a small molecule positive modulator of hepatocyte growth factor (HGF)/MET, is neuroprotective in a TDP-43 mouse model of amyotrophic lateral sclerosis</strong></td>
<td>Andree-Anne Berthiaume, Ph.D., Athira Pharma</td>
<td>PRECLINICAL</td>
<td>Poster, Pipeline</td>
</tr>
<tr>
<td>6</td>
<td><strong>Discovery and characterization of BHV-7000: a novel KV7.2/7.3 activator for the treatment of epilepsy</strong></td>
<td>Presenter: Steven Dworetzky, Ph.D., Biohaven Pharmaceuticals</td>
<td>PRECLINICAL</td>
<td>Poster, Pipeline</td>
</tr>
<tr>
<td>7</td>
<td><strong>NPT520-34, a clinical stage small molecule therapeutic candidate that targets neurodegenerative processes arising from mitochondrial dysfunction in Parkinson’s disease and other neurodegenerative disorders</strong></td>
<td>Diana L. Price, Ph.D., Neuropore Therapies, Inc.</td>
<td>CLINICAL STAGE</td>
<td>Poster, Pipeline</td>
</tr>
<tr>
<td>8</td>
<td><strong>MONARCH and ADMIRAL Interim Analyses: Ongoing, Open-label, Phase 1/2a Studies in US and UK Investigating Safety and Drug Exposure of STK-001, an Antisense Oligonucleotide (ASO), in Children and Adolescents with Dravet Syndrome (DS)</strong></td>
<td>Presenter: Javier Avendano, M.D. Kimberly A. Parkerson, M.D., Stoke Therapeutics</td>
<td>CLINICAL STAGE</td>
<td>Poster, Pipeline</td>
</tr>
<tr>
<td>9</td>
<td><strong>Valbenazine effects on the dopamine system in humans, as measured by [11C]-PHNO positron emission tomography (PET)</strong></td>
<td>Daniel Albrecht, Ph.D., Neurocrine Biosciences, Inc</td>
<td>CLINICAL STAGE</td>
<td>Poster, Pipeline</td>
</tr>
<tr>
<td>#</td>
<td>TITLE</td>
<td>AUTHORS/CONTACTS</td>
<td>STAGE</td>
<td>TYPE</td>
</tr>
<tr>
<td>----</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------</td>
<td>----------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>10</td>
<td><strong>XEN1101, a novel potassium channel modulator: interim data from an ongoing, long-term, open-label extension of a phase 2b study (X-TOLE) in adults with focal epilepsy</strong> -</td>
<td>Jacqueline French, M.D., New York University Grossman School of Medicine and NYU Langone Health</td>
<td>CLINICAL STAGE</td>
<td>Poster, Pipeline</td>
</tr>
<tr>
<td>12</td>
<td><strong>Metaplastic effects of ketamine metabolite (2R,6R)-hydroxynorketamine on hippocampal synaptic plasticity and transmission in mice</strong></td>
<td>Kyle A. Brown, Ph.D., University of Maryland School of Medicine</td>
<td></td>
<td>Featured Poster - Monday</td>
</tr>
<tr>
<td>13</td>
<td><strong>Dectin-1 signaling on colonic γδ T cells promotes psychosocial stress responses</strong></td>
<td>Xiaolei Zhu, M.D., Ph.D., Johns Hopkins University</td>
<td></td>
<td>Featured Poster - Monday</td>
</tr>
<tr>
<td>14</td>
<td><strong>EEG Phenotyping as a loop translation tool to Identify and select new neurotherapeutics</strong></td>
<td>Venceslas Duveau, Ph.D., SynapCell SAS</td>
<td></td>
<td>Featured Poster - Monday</td>
</tr>
<tr>
<td>15</td>
<td><strong>The amygdala-kindling model: Toward the development of a high performance screening platform to accelerate the identification of novel anti-seizure medications</strong></td>
<td>Julien Volle, Ph.D., SynapCell SAS</td>
<td></td>
<td>Featured Poster - Monday</td>
</tr>
<tr>
<td>16</td>
<td><strong>Opening the blood-brain barrier for drug and gene therapy with MRI-guided TMS: A feasibility study</strong></td>
<td>Ira Weinberg, M.D., Ph.D., Weinberg Medical Physics, Inc.</td>
<td></td>
<td>Featured Poster - Tuesday</td>
</tr>
<tr>
<td>17</td>
<td><strong>Ampicillin for Major Depressive Disorder by Targeting Glial Glutamate Transporter in an Animal Model</strong></td>
<td>Shafiqur Rahman Ph.D., South Dakota State University</td>
<td></td>
<td>Featured Poster - Tuesday</td>
</tr>
<tr>
<td>18</td>
<td><strong>Bidirectional transcription at the PPP2R2B gene locus in spinocerebellar ataxia type 12</strong></td>
<td>Pan P. Li, Ph.D., Johns Hopkins University School of Medicine</td>
<td></td>
<td>Featured Poster - Tuesday</td>
</tr>
<tr>
<td>#</td>
<td>TITLE</td>
<td>AUTHORS/CONTACTS</td>
<td>STAGE</td>
<td>TYPE</td>
</tr>
<tr>
<td>-----</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-------</td>
<td>--------------------</td>
</tr>
<tr>
<td>19</td>
<td>The expression of PPP2R2B gene in spinocerebellar ataxia type 12 is affected by the length and composition of the CAG repeat</td>
<td>Pan P. Li, Ph.D., Johns Hopkins University School of Medicine</td>
<td></td>
<td>Featured Poster - Tuesday</td>
</tr>
<tr>
<td>20</td>
<td>Disease modifying effects of gut microbiome balancing-biological response modifier glucans in Parkinson's disease – Results of a pilot clinical study</td>
<td>Samuel JK Abraham M.D., Ph.D., FRCP(L), University of Yamanashi</td>
<td></td>
<td>Featured Poster - Tuesday</td>
</tr>
<tr>
<td>21</td>
<td>ATH-1020, a small molecule positive modulator of hepatocyte growth factor (HGF)/MET, has robust and persistent therapeutic effects in a rat model of diabetic neuropathic pain</td>
<td>Jewel L. Johnston, Ph.D., Athira Pharma</td>
<td></td>
<td>POSTER ONLY</td>
</tr>
<tr>
<td>22</td>
<td>Fosgonimeton, a novel, small molecule positive modulator of the HGF/MET system is neuroprotective in primary neuron culture</td>
<td>Wei Wu, Ph.D., Athira Pharma</td>
<td></td>
<td>POSTER ONLY</td>
</tr>
<tr>
<td>23</td>
<td>Best Practice Guidelines for Remote Central Rating in CNS Clinical Trials</td>
<td>Pam Ventola, Ph.D., Yale University</td>
<td></td>
<td>POSTER ONLY</td>
</tr>
<tr>
<td>25</td>
<td>The NIH HEAL Initiative/National Institute of Neurological Disorders and Stroke’s Early Phase Pain Investigation Clinical Network (EPPIC-Net): Year 3 Update</td>
<td>Kevin T. Jones, Ph.D., National Institutes of Health</td>
<td></td>
<td>POSTER ONLY</td>
</tr>
<tr>
<td>26</td>
<td>Discovery and Development of New Antiepileptic Drugs Through NINDS Blueprint Neurotherapeutics Network (BPN)</td>
<td>Shamsi Raeissi, Ph.D., NINDS</td>
<td></td>
<td>POSTER ONLY</td>
</tr>
<tr>
<td>27</td>
<td>A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of XEN1101 as an adjunctive therapy in the treatment of primary generalized tonic-clonic seizures</td>
<td>Christopher Kenney, M.D., FAAN, Xenon Pharmaceuticals</td>
<td></td>
<td>POSTER ONLY</td>
</tr>
<tr>
<td>#</td>
<td>TITLE</td>
<td>AUTHORS/CONTACTS</td>
<td>STAGE</td>
<td>TYPE</td>
</tr>
<tr>
<td>----</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------</td>
<td>------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>28</td>
<td><strong>The CURE Epilepsy Catalyst Award: Grant Opportunity For Translational Research in Epilepsy</strong></td>
<td>Priya Balasubramanian, Ph.D., CURE Epilepsy</td>
<td>ANNOUNCEMENT</td>
<td>POSTER ONLY</td>
</tr>
<tr>
<td>29</td>
<td><strong>National Institute of Neurological Disorders and Stroke’s Ultra-Rare Gene-based Therapy (URGenT) Network</strong></td>
<td>Tjerignimin Silue, Ph.D., NINDS</td>
<td>ANNOUNCEMENT</td>
<td>POSTER ONLY</td>
</tr>
<tr>
<td>30</td>
<td><strong>Design of two parallel randomized, double-blind, placebo-controlled phase 3 studies to evaluate the safety and efficacy of XEN1101 as adjunctive therapy in the treatment of focal onset epilepsy</strong></td>
<td>Jo Wagner, Xenon Pharmaceuticals</td>
<td>POSTER ONLY</td>
<td>POSTER ONLY</td>
</tr>
<tr>
<td>31</td>
<td><strong>The need for continued education and training opportunities in clinical research: Taking a deep dive into a 100% audit</strong></td>
<td>Matthew Gooden, MS, NINDS</td>
<td>POSTER ONLY</td>
<td>POSTER ONLY</td>
</tr>
<tr>
<td>32</td>
<td><strong>The HEAL Pain Therapeutics Development Program: Status and Pipeline</strong></td>
<td>Mary Ann Pelleymounter, Ph.D., National Institutes of Health</td>
<td>ANNOUNCEMENT</td>
<td>POSTER ONLY</td>
</tr>
</tbody>
</table>
ASENT Leadership

PROGRAM COMMITTEE

CHAIRS
Sharon Tamir
*Mitsubishi Tanabe*
Dietrich Haubenberger, MD, MHSc
Neurocrine Biosciences

COMMITTEE MEMBERS
C Anthony Altar, PhD
Splice Therapeutics
Enrique Carrazana, MD
Neurelis
Suhayl Dhib-Jalbut, MD
Rutgers-Robert Wood Johnson Medical School
Debra Ehrlich, MD, MS
NINDS
Gail Farfel, PhD
ProMIS
Samuel A. Frank, MD, FAAN, FANA
Beth Israel Deaconess Medical Center
Aditya Joshi, MD
University of Pennsylvania
Nancy Santilli, MSN
Human Care Systems
Carolyn Tallon, PhD
Johns Hopkins University
Danilo Vitorovic, MD
Loma Linda University
Lauren Reoma, MD
NINDS
Ludy Shih, MD, MMSc
Boston University Medical School

EX-OFFICIO PROGRAM COMMITTEE MEMBERS
Thomas P. Sutula, MD, PhD
*University of Wisconsin, Madison*
Andrew J. Cole, MD
Massachusetts General Hospital/Harvard
Bennett Lavenstein, MD
Children’s National Health System
Amir Tamiz, PhD
NINDS

BOARD OF DIRECTORS

EXECUTIVE COMMITTEE
Thomas P. Sutula, MD, PhD, PRESIDENT
*University of Wisconsin, Madison*
Andrew J. Cole, MD, INCOMING PRESIDENT
Massachusetts General Hospital/Harvard

COMMITTEE MEMBERS
C Anthony Altar, PhD,
Splice Therapeutics
Enrique Carrazana, MD
Neurelis
Amy Chappell, MD
Elam
Stewart A. Factor, DO
Emory University School of Medicine
Gail Farfel, PhD
ProMIS
Dietrich Haubenberger, MD, MHSc
Neurocrine Biosciences
Aditya Joshi, MD
University of Pennsylvania
Bennett L., Lavenstein, MD
Children’s Hospital Medical Center

EX-OFFICIO BOARD
Amir Tamiz, PhD
NINDS
M. Maral Mouradian, MD
Rutgers University
REGISTRATION DETAILS

ANNUAL MEETING REGISTRATION

https://asent.org/Annual-Meeting

Annual Meeting Registration Deadline: March 13, 2023

Contact us at caroline@asent.org for additional information.